1266 related articles for article (PubMed ID: 19118249)
41. Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data.
Brar SS; ten Berg J; Marcucci R; Price MJ; Valgimigli M; Kim HS; Patti G; Breet NJ; DiSciascio G; Cuisset T; Dangas G
J Am Coll Cardiol; 2011 Nov; 58(19):1945-54. PubMed ID: 22032704
[TBL] [Abstract][Full Text] [Related]
42. Usefulness of aspirin resistance after percutaneous coronary intervention for acute myocardial infarction in predicting one-year major adverse coronary events.
Marcucci R; Paniccia R; Antonucci E; Gori AM; Fedi S; Giglioli C; Valente S; Prisco D; Abbate R; Gensini GF
Am J Cardiol; 2006 Nov; 98(9):1156-9. PubMed ID: 17056317
[TBL] [Abstract][Full Text] [Related]
43. New coating stent design for patients with high-risk coronary lesions for thrombotic events: early and long-term results of the Camouflage registry.
Perez G; Rodriguez-Granillo AM; Mieres J; Llaurado C; Rubilar B; Risau G; Fernandez-Pereira C; Rodriguez AE
J Invasive Cardiol; 2009 Aug; 21(8):378-82. PubMed ID: 19652248
[TBL] [Abstract][Full Text] [Related]
44. Long-term outcomes by clopidogrel duration and stent type in a diabetic population with de novo coronary artery lesions.
Brar SS; Kim J; Brar SK; Zadegan R; Ree M; Liu IL; Mansukhani P; Aharonian V; Hyett R; Shen AY
J Am Coll Cardiol; 2008 Jun; 51(23):2220-7. PubMed ID: 18534267
[TBL] [Abstract][Full Text] [Related]
45. High on-treatment platelet reactivity to both aspirin and clopidogrel is associated with the highest risk of adverse events following percutaneous coronary intervention.
Breet NJ; van Werkum JW; Bouman HJ; Kelder JC; Harmsze AM; Hackeng CM; ten Berg JM
Heart; 2011 Jun; 97(12):983-90. PubMed ID: 21478385
[TBL] [Abstract][Full Text] [Related]
46. Calcium-channel blockers decrease clopidogrel-mediated platelet inhibition.
Gremmel T; Steiner S; Seidinger D; Koppensteiner R; Panzer S; Kopp CW
Heart; 2010 Feb; 96(3):186-9. PubMed ID: 19687016
[TBL] [Abstract][Full Text] [Related]
47. Clinical outcomes of high on-treatment platelet reactivity in Koreans receiving elective percutaneous coronary intervention (from results of the CROSS VERIFY study).
Park KW; Jeon KH; Kang SH; Oh IY; Cho HJ; Lee HY; Kang HJ; Park SK; Koo BK; Oh BH; Park YB; Kim HS
Am J Cardiol; 2011 Dec; 108(11):1556-63. PubMed ID: 21880289
[TBL] [Abstract][Full Text] [Related]
48. Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: the VERIfy Thrombosis risk ASsessment (VERITAS) study.
Malinin A; Pokov A; Spergling M; Defranco A; Schwartz K; Schwartz D; Mahmud E; Atar D; Serebruany V
Thromb Res; 2007; 119(3):277-84. PubMed ID: 16563469
[TBL] [Abstract][Full Text] [Related]
49. Predictors of heightened platelet reactivity despite dual-antiplatelet therapy in patients undergoing percutaneous coronary intervention.
Price MJ; Nayak KR; Barker CM; Kandzari DE; Teirstein PS
Am J Cardiol; 2009 May; 103(10):1339-43. PubMed ID: 19427425
[TBL] [Abstract][Full Text] [Related]
50. Posttreatment platelet reactivity on clopidogrel is associated with the risk of adverse events after off-pump coronary artery bypass.
Youn YN; Yi G; Lee S; Joo HC; Yoo KJ
Am Heart J; 2014 Jun; 167(6):818-25. PubMed ID: 24890530
[TBL] [Abstract][Full Text] [Related]
51. Nonrandomized comparison of coronary artery bypass surgery and percutaneous coronary intervention for the treatment of unprotected left main coronary artery disease in octogenarians.
Rodés-Cabau J; Deblois J; Bertrand OF; Mohammadi S; Courtis J; Larose E; Dagenais F; Déry JP; Mathieu P; Rousseau M; Barbeau G; Baillot R; Gleeton O; Perron J; Nguyen CM; Roy L; Doyle D; De Larochellière R; Bogaty P; Voisine P
Circulation; 2008 Dec; 118(23):2374-81. PubMed ID: 19029471
[TBL] [Abstract][Full Text] [Related]
52. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study.
Patti G; Colonna G; Pasceri V; Pepe LL; Montinaro A; Di Sciascio G
Circulation; 2005 Apr; 111(16):2099-106. PubMed ID: 15750189
[TBL] [Abstract][Full Text] [Related]
53. A point-of-care platelet function assay and C-reactive protein for prediction of major cardiovascular events after drug-eluting stent implantation.
Park DW; Lee SW; Yun SC; Song HG; Ahn JM; Lee JY; Kim WJ; Kang SJ; Kim YH; Lee CW; Park SW; Park SJ
J Am Coll Cardiol; 2011 Dec; 58(25):2630-9. PubMed ID: 22152948
[TBL] [Abstract][Full Text] [Related]
54. Differential prognostic impact of high on-treatment platelet reactivity among patients with acute coronary syndromes versus stable coronary artery disease undergoing percutaneous coronary intervention.
Park DW; Ahn JM; Song HG; Lee JY; Kim WJ; Kang SJ; Yun SC; Lee SW; Kim YH; Lee CW; Park SW; Park SJ
Am Heart J; 2013 Jan; 165(1):34-42.e1. PubMed ID: 23237131
[TBL] [Abstract][Full Text] [Related]
55. Two-year clinical outcome after successful implantation of drug-eluting and bare metal stents in diabetic patients: results from a real-world single center registry.
Dou KF; Xu B; Yang YJ; Chen JL; Qiao SB; Li JJ; Qin XW; Liu HB; Wu YJ; Chen J; Yao M; You SJ; Yuan JQ; Dai J; Gao RL
Chin Med J (Engl); 2009 Mar; 122(6):612-6. PubMed ID: 19323921
[TBL] [Abstract][Full Text] [Related]
56. Clopidogrel is associated with better in-hospital and 30-day outcomes than ticlopidine after coronary stenting.
L'Allier PL; Aronow HD; Cura FA; Bhatt DL; Albirini A; Schneider JP; Topol EJ; Ellis SG
Can J Cardiol; 2003 Aug; 19(9):1041-6. PubMed ID: 12915931
[TBL] [Abstract][Full Text] [Related]
57. Effectiveness of in-laboratory high-dose clopidogrel loading versus routine pre-load in patients undergoing percutaneous coronary intervention: results of the ARMYDA-5 PRELOAD (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) randomized trial.
Di Sciascio G; Patti G; Pasceri V; Gatto L; Colonna G; Montinaro A;
J Am Coll Cardiol; 2010 Aug; 56(7):550-7. PubMed ID: 20688209
[TBL] [Abstract][Full Text] [Related]
58. Residual platelet reactivity is an independent predictor of myocardial injury in acute myocardial infarction patients on antiaggregant therapy.
Marcucci R; Paniccia R; Antonucci E; Poli S; Gori AM; Valente S; Giglioli C; Lazzeri C; Prisco D; Abbate R; Gensini GF
Thromb Haemost; 2007 Oct; 98(4):844-51. PubMed ID: 17938810
[TBL] [Abstract][Full Text] [Related]
59. Prognosis of patients suffering an acute coronary syndrome while already under chronic clopidogrel therapy.
Bonello L; De Labriolle A; Lemesle G; Steinberg DH; Roy P; Torguson R; Suddath WO; Satler LF; Kent KM; Pichard AD; Waksman R
Catheter Cardiovasc Interv; 2009 Jun; 73(7):866-70. PubMed ID: 19198009
[TBL] [Abstract][Full Text] [Related]
60. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation.
Geisler T; Langer H; Wydymus M; Göhring K; Zürn C; Bigalke B; Stellos K; May AE; Gawaz M
Eur Heart J; 2006 Oct; 27(20):2420-5. PubMed ID: 17005534
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
